JMP Securities Reiterates Market Outperform on Structure Therapeutics, Maintains $91 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Structure Therapeutics (NASDAQ:GPCR), maintaining a price target of $91.
November 20, 2023 | 2:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst reaffirms a positive 'Market Outperform' rating on Structure Therapeutics, with a steady price target of $91.
The reiteration of a 'Market Outperform' rating by JMP Securities is a strong positive signal to the market, suggesting that the analyst sees continued potential in GPCR's performance. The maintenance of a $91 price target indicates a belief in the company's value proposition and growth prospects. This could lead to increased investor confidence and a potential short-term uplift in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100